osteosarcoma arising in bone Paget disease

Summary

osteosarcoma arising in bone Paget disease (MONDO:0004275) is a disease. A subtype of bone carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	osteosarcoma arising in bone Paget disease
Mondo ID	MONDO:0004275
DOID	DOID:7542
NCIT	C6469
UMLS	C0334546
MedGen	569679
GARD	0023906
Is cancer (heuristic)	no

Also known as: osteosarcoma arising in bone Paget’s disease · osteosarcoma arising in osseous Paget’s disease · osteosarcoma arising in osteitis deformans · osteosarcoma arising in Paget disease of bone · osteosarcoma arising in Paget’s disease of bone · Paget osteosarcoma · Paget’s osteosarcoma

Disease family

This is a subtype of bone carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › musculoskeletal system disorder › musculoskeletal system cancer › bone cancer › bone carcinoma › osteosarcoma arising in bone Paget disease

Related subtypes (6): paranasal sinus carcinoma, bone squamous cell carcinoma, adamantinoma, growth hormone-producing pituitary gland carcinoma, pituitary adenocarcinoma, metastatic carcinoma in the bone

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.